Alfuzosin (CAS 81403-80-7) Suppliers and Product Information

Alfuzosin is a selective alpha-1 receptor blocker used to treat benign prostatic hyperplasia (BPH) and hypertension. It belongs to the quinazoline derivative class and works by relaxing smooth muscles in the prostate and bladder neck, reducing urinary flow resistance. Alfuzosin has a quick onset of action and minimal cardiovascular side effects compared to other BPH medications.

Pharmacokinetics: Alfuzosin is well-absorbed, reaching peak blood concentration in 0.5-3 hours with 64% bioavailability. It has linear pharmacokinetics within the therapeutic dose range and is 87% bound to plasma proteins. The drug is primarily eliminated through liver metabolism, with 75-91% excreted in feces and 15-30% in urine. The elimination half-life is 4-8 hours.

Usage: For BPH treatment, the typical dosage is 7.5 to 10mg daily, divided into three doses. For hypertension, the same dosage applies. It's important to note that alfuzosin hydrochloride should not be used concurrently with calcium antagonists and alpha blockers.

Frequently Asked Questions about Alfuzosin

Q: What is the main use of Alfuzosin?

A: Alfuzosin is primarily used to treat benign prostatic hyperplasia (BPH) and hypertension. It helps alleviate urinary symptoms associated with BPH by relaxing smooth muscles in the prostate and bladder neck.

Q: How does Alfuzosin differ from other alpha-1 blockers?

A: Alfuzosin is more selective for the α1A receptor subtype in the prostate gland compared to those in vascular tissue. This selectivity results in fewer cardiovascular side effects than some other alpha-1 blockers like terazosin and doxazosin.

Q: Are there any special considerations for elderly patients taking Alfuzosin?

A: In patients over 75 years old, Alfuzosin is absorbed faster and reaches higher peak blood concentrations. The area under the curve (AUC) is also higher than in younger patients, while the volume of distribution may be reduced and the elimination half-life extended.

Q: Can Alfuzosin be used in patients with liver or kidney problems?

A: In patients with renal insufficiency, the pharmacokinetics of Alfuzosin do not change significantly. However, in patients with liver dysfunction, blood drug concentrations, elimination half-life, and AUC values are all increased, and the free fraction of the drug is also higher. Caution should be exercised in these patients.